2025 Volume 52 Issue 2 Pages 353-361
Dyslipidemia is a major risk factor for atherosclerotic cardiovascular disease (ASCVD), and its management is important for the prevention of ASCVD events. Since the publication of the Guidelines for the Treatment of Hyperlipidemia in 1997, the Japan Atherosclerosis Society (JAS) has revised the guidelines every five years in response to the accumulation of new knowledge from epidemiological studies and clinical trials, and in 2022 issued the latest version "Guidelines for the Prevention of ASCVD, 2022". Revisions from the previous version include the addition of atherothrombotic cerebral infarction to secondary prevention diseases, the addition of casual triglyceride levels to the diagnostic criteria for dyslipidemia, the adoption of the Hisayama-cho score as a risk stratification tool for primary prevention, and partial changes to the management targets for diabetes. In Japan, health checkups are mandatory for employees, and specific health checkups are also conducted for family members, etc. These checkups are conducted by health checkup facilities, and depending on the data obtained, the examinees must be referred to medical institutions or sent for health guidance. Many health checkup facilities use the standard values based on the Ministry of Health, Labor and Welfare's "Standard Health Checkup and Health Guidance Program", but this standard differs slightly from the intent of the JAS guideline. In this article, after providing an overview of the "Guidelines for the Prevention of ASCVD, 2022", I will suggest how it can be used in health checkup facilities.
